Network meta-analysis of longitudinal data using fractional polynomials

Statistics in Medicine

Volumn 34, Issue 15, 2015, Pages 2294-2311

  Jansen, Jeroen P ^a,b   Vieira, M C ^c   Cope, S ^d  

^a Redwood Outcomes   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Previously at Mapi   (United States)

^d MAPI Consultancy   (Canada)

Author keywords

Fractional polynomials; Mixed treatment comparison; Network meta analysis; Repeated measures; Study level data

Indexed keywords

ARTICLE; BAYES THEOREM; DATA ANALYSIS; FRACTIONAL POLYNOMIAL; HUMAN; KNEE OSTEOARTHRITIS; LONGITUDINAL STUDY; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND ORDER FRACTIONAL POLYNOMIAL; STATISTICAL ANALYSIS; STATISTICAL MODEL; STIMULUS GENERALIZATION; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

VISCOSUPPLEMENT;

BAYES THEOREM; HUMANS; MODELS, STATISTICAL; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VISCOSUPPLEMENTS;

EID: 84930380259     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6492     Document Type: Article

References (57)

1. Inthout J, Ioannidis JP, Borm GF. Obtaining evidence by a single well-powered trial or several modestly powered trials. Statistical Methods in Medical Research2012. DOI: 10.1177/0962280212461098.
2. Higgins JPT, Whitehead A. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine 1996; 15:2733-2749.
3. Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Statistics in Medicine 2003; 22(19): 2995-3016.
4. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004; 23:3105-3124.
5. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal 2005; 331:897-900.
6. Salanti G, Higgins JPT, Ades AE, Ioannidis JPA. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008; 17(3): 279-301.
7. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, Bradburn M, Eastwood AJ, International Stroke Trial Collaborative Group. Indirect comparisons of competing interventions. Health Technology Assessment 2005; 9(26): 1-149.
8. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting indirect treatment comparisons & network meta-analysis for health care decision-making: report of the ISPOR task force on good research practices - Part 1. Value in Health 2011; 14 :417-428.
9. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barret A. Conducting indirect treatment comparison and network meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices - Part 2. Value in Health 2011; 14:429-437.
10. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials, 2011. Available from: http://www.nicedsu.org.uk [Accessed on 25 September 2012].
11. Trikalinos TA, Olkin I. Meta-analysis of effect sizes reported at multiple time points: a multivariate approach. Clinical Trials 2012; 9(5): 610-620.
12. Jones AP, Riley RD, Williamson PR, Whitehead A. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clinical Trials 2009; 6(1): 16-27.
13. Ishak KJ, Platt RW, Joseph L, Hanley JA, Caro JJ. Meta-analysis of longitudinal studies. Clinical Trials 2007; 4(5): 525-539.
14. Peters JL, Mengersen KL. Meta-analysis of repeated measures study designs. Journal of Evaluation in Clinical Practice 2008; 14:941-950.
15. Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. British Medical Journal 2010; 341:c4675.
16. Dakin HA, Welton NJ, Ades AE, Collins S, Orme M, Kelly S. Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. Statistics in Medicine 2011; 30(20): 2511-2535.
17. Lu G, Ades AE, Sutton AJ, Cooper NJ, Briggs AH, Caldwell DM. Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine 2007; 26(20): 3681-3699.
18. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling (with discussion). Applied Statistics 1994; 43:429-467.
19. Lambert PC, Smith LK, Jones DR, Botha JL. Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects. Statistics in Medicine 2005; 24:3871-3885.
20. Bossard N, Descotes F, Bremond AG, Bobin Y, De Saint Hilaire P, Golfier F, Awada A, Mathevet PM, Berrerd L, Barbier Y, Estève J. Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer. Breast Cancer Research and Treatment 2003; 82:47-59.
21. Berger U, Schafer J, Ulm K. Dynamic Cox modelling based on fractional polynomials: time-variations in gastric cancer prognosis. Statistics in Medicine 2003; 22:1163-1180.
22. Bagnardi V, Zambon A, Quatto P, Corrao G. Flexible meta-regression functions for modeling aggregate dose response data, with an application to alcohol and mortality. American Journal of Epidemiology 2004; 159:1077-1086.
23. Sauerbrei W, Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. Journal of the Royal Statistical Society Series A - Statistics in Society 1999; 162:71-94.
24. Sauerbrei W, Royston P, Look M. A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation. Biometrical Journal 2007; :453-473.
25. Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Medical Research Methodololog 2011; 9:61.
26. Jansen JP, Cope S. Meta-regression models to assess heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Medical Research Methodololog 2012; 12:152.
27. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Statistics in Medicine 2009; 28:1861-1881.
28. Akaike H. Information theory and an extension of the maximum likelihood principle. Second International Symposium on Information Theory 1973; 1:267-281.
29. Dempster AP. The direct use of likelihood for significance testing. Statistics and Computing 1997; 7:247-252.
30. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society, Series B 2002; 64:583-639.
31. Dagenais S, Garbedian S. Systematic review of the prevalence of radiographic primary hip osteoarthritis. Clinical Orthopaedics and Related Research 2009; 467:623-637.
32. Pisoni C, Giardini A, Majani G, Maini M. International Classification of Functioning, Disability, and Health (ICF) core sets for osteoarthritis. A useful tool in the follow-up of patients after joint arthroplasty. European Journal of Physical and Rehabilitation Medicine 2008; 44:377-385.
33. Wenham CYJ, Conaghan PG. Imaging the painful osteoarthritic knee joint: what have we learned?Nature Clinical Practice Rheumatology 2009; 5:149-158.
34. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database of Systematic Reviews 2006; 19(2): CD005321.
35. Divine JG, Zazulak BT, Hewett TE. Viscosupplementation for knee osteoarthritis: a systematic review. Clinical Orthopaedics and Related Research 2007; 455:113-122.
36. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M, Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases 2003; 62:1145-1155.
37. Simon LS, Lipman AG, Jacox AK, Caudill-Slosberg M, Gill LH, Keefe FJ, Kerr KL, Minor MA, Sherry DD, Vallerand AH, Vasudevan S. Guidelines for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. In APS Clinical Practice Guidelines Series, (2nd edn). American Pain Society: Glenview, IL; 2002.
38. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, KD Brandt, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, P Tugwell. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16:137-162.
39. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan study group. The Journal of Rheumatology 1998; 25(11): 2203-2212.
40. Altman RD, Rosen JE, Bloch DA, Hatoum HT, Korner P. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Seminars in Arthritis and Rheumatism 2009; 39(1): 1-9.
41. Carrabba M, Paresce E, Angelini M, Re KA, Torchiana EEM, Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. European Journal of Rheumatology & Inflammation 1995; 15(1): 25-31.
42. Corrado EM, Peluso GF, Gigliotti S, De Durante C, Palmieri D, Savoia N, Oriani GO, GF Tajana. The effects of intra-articular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evaluations. European Journal of Rheumatology & Inflammation 1995; 15(1): 47-56.
43. Cubukçu D, Ardiç F, Karabulut N, Topuz O. Hylan G-F 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment. Clinical Rheumatology 2005; 24(4): 336-341.
44. Dickson DJ, Hosie G, English JR. A double-blind, placebo controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. Journal of Clinical Research 2001; 4:41-52.
45. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993; 1(2): 97-103.
46. Henderson EB, Smith EC, Pegley F, Blake DR. Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Annals of the Rheumatic Diseases 1994; 53(8): 529-534.
47. Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford) 1999; 38(7): 602-607.
48. Jubb RW, Piva S, Beinat L, Dacre J, Gishen P. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. International Journal of Clinical Practice 2003; 57(6): 467-474.
49. Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford) 2002; 41(11): 1240-1128.
50. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis and Cartilage 2006; 14:154-162.
51. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Current Therapeutic Research, Clinical and Experimental 1994; 55(3): 220-232.
52. Stitik TP, Blacksin MF, Stiskal DM, Kim JH, Foye PM, Schoenherr L, Choi ES, Chen B, HJ Saunders, Nadler SF. Efficacy and safety of hyaluronan treatment in combination therapy with home exercise for knee osteoarthritis pain. Archives of Physical Medicine and Rehabilitation 2007; 88(2): 135-141.
53. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clinical Therapeutics 1998; 20(3): 410-423.
54. Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, Vetter G, Balazs E. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clinical Therapeutics 1999; 21(9): 1549-1562.
55. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique, and future directions. Statistics in Medicine 2009; 28:3049-3067.
56. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Guobing L, Ades AE. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials, 2011. Available from: http://www.nicedsu.org.uk[Accessed on 25 September 2012].
57. Riley RD. Multivariate meta-analysis: the effect of ignoring within-study correlation. Journal of the Royal Statistical Society Series A - Statistics in Society 2009; 172:789-811.